Drugs / MIR 19 ®
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05184127 | Apr → Sep 2021 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05783206 | Feb 2022 → Jul 2023 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIR 19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05184127 ↗ |
| Known as | siR-7-EM/KK-46 | “We aimed to investigate safety and efficacy of a SARS-CoV-2-specific siRNA-peptide dendrimer formulation MIR 19® (siR-7-EM/KK-46) targeting a conserved sequence in known...” PMID 36721963 ↗ Feb 2023 |
| Action | Inhibit | “SARS-CoV-2 inhibition with MIR 19 ® could potentially reduce pulmonary inflammation” NCT05184127 ↗ |
| Modality | Small interfering RNA (siRNA) | “a SARS-CoV-2-specific siRNA-peptide dendrimer formulation MIR 19®” PMID 36721963 ↗ Feb 2023 |
| Route | Inhaled | “3.7 mg of the MIR 19 ® via inhalation route” NCT05184127 ↗ |